Genes & biomarkers

MET exon 14 and amplification

MET · exon 14 skipping / amplification

MET exon 14 skipping and MET amplification are distinct findings.

Sources checked · Introductory guide

On this page

What does this result mean?

Read beyond the gene name. Alterations causing exon 14 skipping differ from amplification, which means increased gene copy number.[1]

How does it connect to treatment?

MET inhibitors such as capmatinib may be considered for metastatic non-small cell lung cancer with MET exon 14 skipping. That indication does not automatically include MET amplification or protein expression.[2]

What should I check in my report?

Ask whether the result is exon 14 skipping, amplification or protein expression. If detected after another targeted therapy, review its relationship to the original target and resistance.

Questions for your care team

  • Does my MET result show exon 14 skipping or amplification?
  • Which treatments or trials fit my cancer type, stage and previous treatment?

Sources and scope

Source documents are in English.

Entries summarize and translate linked official public sources. The source-check date records when those sources were checked; it does not indicate a clinician’s review.

  1. NCI · Non-Small Cell Lung Cancer Treatment (PDQ) (opens in a new tab)
  2. NCI · Capmatinib (opens in a new tab)

General information based on official public sources. This is not a complete list of uses or side effects. Individual treatment decisions require your care team and current source documents. US-source uses do not establish local approval or reimbursement.

Related entries

MET exon 14 and amplification | Cancer Encyclopedia | My Chemo Diary